A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment

Bielack, Stefan S.; Soussain, Carole; Fox, Christopher P.; Houillier, Caroline; Murciano, Thais; Osborne, Wendy; Zinzani, Pier Luigi; Rizzari, Carmelo; Schwartz, Stefan

Abstract

High-dose methotrexate (HDMTX) is used in the treatment of a range of adult and childhood cancers. Although HDMTX can provide effective anti-tumor activity with an acceptable safety profile for most patients, delayed methotrexate elimination (DME) develops in a minority of patients receiving HDMTX and may be accompanied by renal dysfunction and potentially life-threatening toxicity. A panel of European physicians with experience in the use of HDMTX as well as of glucarpidase convened to develop a series of consensus statements to provide practical guidance on the prevention and treatment of DME, including the use of glucarpidase. Robust implementation of supportive measures including hyperhydration and urine alkalinization emerged as critical in order to reduce the risk of DME with HDMTX treatment, with leucovorin rescue critical in reducing the risk of DME complications. Early recognition of DME is important to promptly implement appropriate treatment including, intensified hydration, high-dose leucovorin and, when appropriate, glucarpidase.

Citation

Bielack, S. S., Soussain, C., Fox, C. P., Houillier, C., Murciano, T., Osborne, W., Zinzani, P. L., Rizzari, C., & Schwartz, S. (2024). A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. Journal of Cancer Research and Clinical Oncology, 150(10), Article 441. https://doi.org/10.1007/s00432-024-05945-6

• Journal Article Type: Article
• Acceptance Date: Sep 9, 2024
• Online Publication Date: Oct 2, 2024
• Publication Date: Oct 2, 2024
• Deposit Date: Dec 2, 2024
• Publicly Available Date: Dec 2, 2024
• Journal: Journal of Cancer Research and Clinical Oncology
• Print ISSN: 0171-5216
• Electronic ISSN: 1432-1335
• Publisher: Springer Verlag
• Peer Reviewed: Peer Reviewed
• Volume: 150
• Issue: 10
• Article Number: 441
• DOI: https://doi.org/10.1007/s00432-024-05945-6
• Public URL: https://nottingham-repository.worktribe.com/output/40290949
• Publisher URL: https://link.springer.com/article/10.1007/s00432-024-05945-6